HOME >> BIOLOGY >> NEWS
Experimental Biology 2007: Today's Research, Tomorrow's Health, April 28-May 2

d novel therapies based on molecules of the innate immune system.

The American Society for Pharmacology and Experimental Therapeutics offers symposia on cannabinoids (a chemical compound in cannabis or marijuana), endocannabinoids (a marijuana-like substance) and pain associated with inflammation, stress, psychiatric disorders, neurodegenerative disorders, and other disorders; the future of pharmacogenomics and its clinical applications; nanotechnology in disease therapeutics; osteoporosis and bone research (a symposium subtitled "no time to be bad to the bone"); toxicology of nanomaterials (including effects on the skin and lungs); the ways in which nicotine modulates adolescent brain plasticity, interacts with other drugs during sensitive developmental periods, and, when used along with alcohol by a woman during pregnancy, alters drug responsiveness in offspring; an examination of why children, adolescents and adults respond differently to antidepressants; studies of how perinatal stress, such as maternal separation, affects drug response and propensity to abuse drugs as an adult; and cardiovascular gene therapy.

The American Physiological Society program includes 16 societal or distinguished lectures and a Physiology Infocus session that focuses on novel technologies in physiology and medicine, such as advances in forensic medicine, new approaches in imaging, and the use of experimental evolution (selecting for particular physiological attributes in large laboratory populations) as a tool of physiological analysis. Other workshops include human subject research ethics and the challenge of presenting basic research in an anti-science, anti-evolution and anti-education era. Among topics for symposia or individual research presentations are: cancer and hypoxia (starving tumors of oxygen) ; pharmacogenomics of estrogen and cardiovascular disease; roles of intestinal epithelia and bacteria in inflammatory disease; and the potential benefits of
'"/>

Contact: Sylvia Wrobel
ebpress@bellsouth.net
770-270-0989
Federation of American Societies for Experimental Biology
25-Feb-2007


Page: 1 2 3 4 5

Related biology news :

1. 38 minority scientists receive travel fellowships to Experimental Biology 2007 in D.C.
2. Experimental Biology 2007 meets in Washington, D.C., April 28-May 2
3. Experimental cancer drugs counter muscle deterioration seen in muscular dystrophy
4. Experimental RNA-based drug kills prostate cancer cells effectively and safely
5. Experimental vaccine protects nonhuman primates when given after exposure to Marburg virus
6. Undergrads compete for American Physiological Society Bruce awards at Experimental Biology
7. Experimental drug reverses key cognitive deficits, pathology in Alzheimers
8. Experimental TB drug effective against resistant and latent mycobacterium tuberculosis
9. Experimental evolution of yeast in the lab may illuminate early events in speciation
10. Advancing the biomedical frontier: Experimental Biology 2006
11. Experimental Biology 2006 meets in San Francisco April 1-5

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Experimental Biology Today Research Tomorrow Health April May

(Date:7/23/2014)... Chrysomya megacephala is commonly found in dead bodies ... time of death, referred to as the post mortem ... C. megacephala from Tamil Nadu is provided for ... characterization through generation of DNA barcoding. This study, significant ... Biodiversity Data Journal . , Chrysomya megacephala ...
(Date:7/23/2014)... New Rochelle, NY -- The potential for clinical ... for transplant-based therapeutic strategies has previously been hindered ... the development of tumors. The ability to use ... for the treatment of heart disease, specifically acute ... Stem Cells and Development , a peer-reviewed ...
(Date:7/23/2014)... MINNETONKA, Minn. , July 23, 2014 /PRNewswire/ ... technology company specializing in clinical study management systems, ... West , a proven life sciences industry executive ... named Chief Operating Officer (COO).  Clareece will be ... and sales growth, operational efficiency and quality product/service ...
Breaking Biology News(10 mins):Dead body feeding larvae useful in forensic investigations 2MedNet Appoints Clareece West As Chief Operating Officer 2
(Date:7/23/2014)... July 23, 2014 ... of Trendlines Agtech , announced it has ... Israel,s leading agricultural thermoplastics applications companies. ... Valentis,s technology combines nanocrystalline cellulose (NCC), a biodegradable, ... additional nanoparticles to produce highly improved polymeric films. ...
(Date:7/23/2014)... regulated information -- UCB today announced an important advance ... topline results from the latest Phase 3 study ... evaluate the efficacy and safety of brivaracetam ... to placebo, as adjunctive treatment in adult focal ... despite treatment with one or two concomitant antiepileptic ...
(Date:7/23/2014)... 2014  Sofinnova Ventures, a Menlo Park ... of Sofinnova Venture Partners IX, L.P. at the hard ... initial fund target of $425 million. Sofinnova ... Consistent with recent funds, SVP IX will provide capital ... along with select investments in earlier stage opportunities. Investments ...
(Date:7/23/2014)... 2014 OncLive® is pleased to ... joined its Strategic Alliance Partnership program. , ... UNC Lineberger will have the opportunity to work ... its cutting-edge research initiatives, community-directed cancer prevention programs, ... work with OncLive to educate their peers by ...
Breaking Biology Technology:Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7Sofinnova Raises $500 Million Biotech Venture Fund 2OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 2OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 3
Cached News: